Background and Rationale Chronic myeloid leukemia (CML) in chronic phase is typically managed with first- or second-generation ATP-competitive tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, and bosutinib (1). While imatinib has offered durable disease control and near-normal life expectancy, it is associated with lower m
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
7713 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes